换一批
换一批Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.
第一作者：
Michel,Delforge
第一单位：
Myeloma Study Group, Belgian Hematological Society, Belgium. michel.delforge@uzleuven.be
作者：
主题词
老年人(Aged);老年人, 80以上(Aged, 80 and over);碱性磷酸酶(Alkaline Phosphatase);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);骨疾病(Bone Diseases);骨重建(Bone Remodeling);硼酸化物(Boronic Acids);细胞分化(Cell Differentiation);女(雌)性(Female);人类(Humans);胞间信号肽类和蛋白质类(Intercellular Signaling Peptides and Proteins);男(雄)性(Male);美法仑(Melphalan);中年人(Middle Aged);多发性骨髓瘤(Multiple Myeloma);成骨细胞(Osteoblasts);泼尼松(Prednisone);吡嗪类(Pyrazines);放射疗法, 辅助(Radiotherapy, Adjuvant)
DOI
10.1111/j.1600-0609.2011.01599.x
PMID
21366694
发布时间
2015-11-19
- 浏览16
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
